Angiographic Characteristics and Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing Impella-Supported High-Risk Percutaneous Coronary Intervention: Insights From the cVAD PROTECT III Study.

9 The PROTECT II (A Prospective, Multi-Center, Randomized Controlled Trial of the IMPELLA RECOVER LP 2.5 System Versus Intra Aortic Balloon Pump [IABP] in Patients Undergoing Non Emergent High Risk PCI) randomized control study demonstrated that among 443 symptomatic patients with complex CAD and severely reduced left ventricular ejection fraction, patients supported with Impella 2.5 had a strong trend towards reduced major adverse events at 90 days compared with those who were supported with an intra-aortic balloon pump. 10 Subsequently, patients from the more contemporary, prospective, multicenter PROTECT III study were compared with similar patients from the PROTECT II study, which demonstrate

also in 5,725 other papers